Aims: This research was conducted to evaluate the hypothesis that gastric ulcers caused by the NSAID diclofenac sodium (DCF) can be prevented by the soluble epoxide hydrolase inhibitor TPPU. Main methods: Mice were administered a single dose of 10, 30 or 100 mg/kg of DCF. Once an ulcerative dose of DCF was chosen, mice were pretreated with TPPU for 7 days at 0.1 mg/kg to evaluate anti-ulcer effects of the sEH inhibitor on anatomy, histopathology, pH, inflammatory markers and epithelial apoptosis of stomachs. Key findings: Diclofenac caused ulceration of the stomach at a dose of 100 mg/kg and a time post dose of 6 h. Ulcers generated under these conditions were associated with a significant increase in the levels of TNF-α and IL-6 in serum and increased apoptosis compared to control mice. Pretreatment with TPPU resulted in a decrease of ulceration in mice treated with DCF with a significant decrease in the level of apoptosis, TNF-α and IL-6 in the serum in comparison to diclofenac-treated mice. TPPU did not affect the pH of the stomach, whereas omeprazole elevated the pH of the stomach as expected. A similar anti-ulcer effect was observed in sEH gene knockout mice treated with DCF. Significance: The sEH inhibitor TPPU decreases the NSAID-induced stomach ulcers.
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) have a long history of use worldwide for the treatment of pain, inflammation and fever. However, the gastrointestinal injury is an important use-limiting side effect of NSAIDs [1] . Approximately 50% of the patients who regularly use NSAIDs display gastric erosion and it is estimated that 15-30% have ulcers. Clinical treatment of this gastrointestinal toxicity is required for 3-4.5% of these patients [2] . Over 30 million people use NSAIDs daily [3] , making gastrointestinal toxicity a major health issue. Though many drugs are available to alleviate NSAID-induced ulceration, inhibitors of soluble epoxide hydrolase (sEH), which decrease pain [4] and inflammation [5] hold promise to decrease such ulcers [1, 6] .
The prostanoid PGE 2 is an important potent lipid mediator of pain and inflammation. However, in the gastrointestinal system, its key function is to protect the stomach from acid secreted by parietal glands through stimulating the production of bicarbonate and mucus. The bicarbonates neutralize acid while the mucus covers the stomach mucosa and prevents contact of acid with mucosal cells. NSAIDs decrease the production of prostanoids, in particular, PGE 2 , but this lack of protective actions of PGE 2 then leads to gastric lesion i.e. erosion and/ulcers of gastric cells. Clinical treatment of gastric ulcers typically involves the use of agents which either decrease the secretion of acid or mimic the actions of PGE 2 (prostaglandin analogs). Omeprazole (OME), the widely used inhibitor of proton pump (H + K + -ATPase) decreases the secretion of acid in the stomach [1] . Despite the wealth of knowledge on the effects of NSAIDs, the mechanistic aspects of NSAID-induced gastric ulcers are still not fully understood. In addition to PGE 2 , multiple other biological pathways seem responsible for the formation of NSAID-induced ulcers [7] [8] [9] [10] [11] . While NSAIDs suppress inflammation, NSAID-induced ulcers are associated with increases in the levels of inflammatory markers such as TNF-α and IL-6 [8, 12] . Although a downstream consequence of COX-2 activity, TNF-α is proposed to play an important role in ulcer pathways activated by prolonged use of NSAID. Anti-TNF-α antibodies for example significantly decrease necrotic and apoptotic lesions associated with ulcers in rats [13, 14] and TNF-α knockout mouse is more resistant to NSAID-induced ulceration [8] .
In addition to its pro-inflammatory functions, TNF-α is known to be a strong inducer of apoptosis through at least several mechanisms [14] . Furthermore, a role for apoptosis in ulceration is supported in numerous studies [15] [16] [17] . Consequently, agents which decrease NSAID-induced apoptosis also decrease stomach ulcers [17] . NSAID-induced apoptosis of gastric cells seems to be driven by not only TNF-α but also by activated endoplasmic reticulum (ER) stress responses to an increase in intracellular Ca 2+ concentrations [18] .
The FitzGerald hypothesis suggests adverse effects of NSAIDs are due, in part, to an alteration in the ratio of thromboxane B2 (TxB2) and prostaglandin E 2 (PGE 2 ) [19] . Inhibitors of sEH not only synergize the anti-inflammatory and analgesic effects of NSAIDs but also balance the TxB2/ PGE 2 altered by treatment with some COX inhibitors [20] . Similarly, genetic deletion of sEH enzyme also leads to alterations in the level of TxB2 [21] . Previously published data suggest sEH inhibitors should protect animals from NSAID driven gastric ulcers [6, 22] . Several sEH inhibitors are in human clinical trials [23, 24] and these molecules display synergistic effects with NSAIDs [5] . Earlier, we demonstrated decreased NSAID-induced intestinal ulcers in mice treated with diclofenac and an inhibitor of sEH [6, 22] . NSAID-induced intestinal ulcer [6] is a serious problem in man. It is more likely that sEH inhibitor would decrease the dose of NSAID and mitigate adverse effect such as ulceration. Therefore, understanding the interactions of inhibition of sEH with NSAID-induced ulceration is important. Here, we evaluated the effects of inhibition of sEH on NSAID-induced gastric ulcers using a mouse model.
The sEH inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohe xyloxy]-benzoic acid (t-AUCB) was shown to decrease piroxicam (a COX inhibitor)-induced inflammatory bowel disease [22] . The sEH inhibitors also decrease apoptosis of cells [25] and ER stress [26, 27] . Therefore, we evaluated the prophylactic effects of N-[1-(1-oxopropyl)-4-piperidinyl]-N′-[4-(trifluoromethoxy)phenyl]-urea (TPPU) on diclo fenac-induced gastric ulcers and the effect of this treatment on markers of inflammation (TNF-α and IL-6), and apoptosis. We selected the most commonly used sEH inhibitor in the field, TPPU, which is highly potent, has high oral availability and a longer half-life than the previously used t-AUCB in mice [28, 29] . Commercial availability of TPPU from several vendors should enable other laboratories to follow up on our results. Ulu et al. [30] recently demonstrated that when given in drinking water TPPU had high oral availability and quickly reached a steady state. Blood levels linearly correlated with the dose in drinking water. Here the effects of TPPU on diclofenac-induced gastric ulcers are reported. In addition, the effect of treatment was studied on pH of the stomach to find out whether sEH inhibitors influence ulceration through modulating pH. Omeprazole, a proton pump inhibitor (PPI) was used as a standard for comparison.
Materials and methods

Materials
Diclofenac (Sigma-Aldrich Co., St. Louis, MO), Mouse TNF-α and IL-6 ELISA kits (Thermo Scientific, Rockford, IL), Pierce® BCA protein assay reagent (Thermo Scientific, Rockford, IL), TACS® 2 TdT-DAB in situ apoptosis detection kit (Trevigen Inc., Gaithersburg, MD) were purchased. TPPU was synthesized previously in the laboratory and is available from commercial sources [28] . All other reagents were of analytical grade.
Animals
Male Swiss Webster mice, C57BL6 and sEH knockout mice in a C57BL6 background weighing 34-41 g were used for the research. Animals were 4 months old. The Institutional Animal Care and Use Committee (IACUC) of the University of California, Davis reviewed and approved the animal protocol. The National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) guidelines has been followed to conduct animal experiments. The animals were maintained in 12 h dark and 12 h light cycle with unlimited access to mouse chow and water. However, animals were kept fasting for 12 h before sacrifice to assess effects of treatment on stomach ulcers. In the cage, animals were kept 2.5 cm above bedding, by use of a wire mesh, to prevent them from eating their feces and bedding during fasting.
The sEH knockout mice were provided originally by Dr. Christopher J. Sinal from the Dr. Frank J. Gonzalez lab (Laboratory of Metabolism, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA) and a colony of knockout mice has been maintained at the University of California, Davis under Mouse Biology Program with repeated back breeding into C57BL6 mice from Jackson Laboratories [31, 32, 33] . Therefore, C57BL6 mice were also used as controls for sEH (−/−) mice.
Induction and scoring of gastric ulcers
Diclofenac-induced ulceration was studied in mice using 3 doses i.e. 10, 30 and 100 mg/kg. Six hours after diclofenac dosing, mice were anesthetized with isoflurane. The abdominal cavity was opened to expose the stomach, which was opened along the greater curvature for evaluating the gastric damage. Ulcer indexes of stomachs exposed to different treatments were calculated as described by Naidu et al. [34] . The images of stomachs were acquired with a digital camera (MA-1000, AmScope, Irvine, CA 92606, United States) mounted on SterioZoom 6 Plus Leica microscope (Leica Microsystems, Buffalo Grove, IL 60089, United States) at 7 × magnification. Briefly, normal colored stomachs and pink colored stomachs were scored as 0 and 0.5 respectively. Spot ulcers were given a score of 1, whereas hemorrhagic streaks were given a score of 1.5. Numbers of ulcers exceeding 3 but b 5 were scored as 2, and the number of ulcers ≥5 were given a score of 3. The final ulcer index was obtained by adding the scores for colored stomach, spot ulcer, hemorrhagic streak and full ulcers. The maximal score, warranted by the ulcer index, is 6. Ulcers were graded by a person not aware of details regarding the dosing. TPPU (0.1 mg/kg/day, 7 days in drinking water) and omeprazole (50 mg/ kg/day, p.o., 5 days) were used to pre-treat the mice before dosing with DCF to test if these agents can decrease the ulcerative effect of the NSAID. The last doses of TPPU and omeprazole were administered 1 h before dosing with DCF. TPPU and OME were administered in 1% PEG400 solution in water. Since TPPU has high oral availability, and its efficacy in reducing intestinal ulcer as a function of oral dose in drinking water has been previously studied [6] , this route of administration was selected as one minimizing trauma to the mice.
Sample collection and tissue processing
Prior to opening the stomach, it was washed with 0.5 mL of saline and the solution was stored in microcentrifuge tubes to measure the pH of gastric contents. Blood samples were collected via cardiac puncture to determine the levels of drugs, TxB2 and PGE 2 in the plasma, and levels of cytokines in the serum. After scoring ulcers in stomachs, the tissues were placed in a neutral buffered formalin solution for 48 h and then transferred to 70% ethanol for further histopathological processing. The tissues were embedded in paraffin, cut into 5 μm size sections and stained (with hematoxylin and eosin) for histopathological evaluation.
Quantification of pH in gastric content
The pHs of gastric contents were measured using pH indicator strips (Catalog number 9590, EMD Chemicals Inc., Gibbstown, NJ) in the range of 1-14 pH units [35] .
Quantification of drugs in blood
Blood samples were collected in tubes containing K 2 EDTA solution (final concentration of 1.2 mg/mL EDTA in the blood) and subsequently mixed and stored on ice until centrifugation. Blood samples were centrifuged at 4000 rpm for 10 m at 4°C. Plasma samples were then collected and stored at −80°C until analyzed by LC-MS/MS [6] .
Quantification of inflammatory markers by ELISA
Separately, blood samples collected from mice were centrifuged at 4000 rpm for 10 m at 4°C without anticoagulant and the supernatant was collected. Serum samples of animals were analyzed to determine the levels of inflammatory markers, such as TNF-α and IL-6, according to instructions from the manufacturers [12, 36] . Mouse TNF-α and IL-6 enzyme-linked immunosorbent assay (ELISA) kits provided microtiter plates pre-coated with TNF-α and IL-6 antibodies respectively. These ELISAs were run in duplicate and values were similar.
Effect of treatment on apoptosis
The terminal deoxynucleotide transferase biotin-dUTP nick-end labeling (TUNEL) method was employed to detect DNA-strand breaks; a sign of gastric cell apoptosis [37, 38] . The effect of treatment on gastric cell apoptosis was determined using the TACS® 2 TdT-DAB in situ apoptosis detection kit of Trevigen Inc. The fixation conditions for the TUNEL assay were optimized before use. TUNEL (+) cells were counted in photos of gastric epithelial cells at 200× magnification.
The sEH activity assay
H substrate labeled sEH activity assays were performed in vitro using stomachs of mice to evaluate the effect of treatment on the activity of sEH and to ensure the genetically knockout animals did not display any activity [39] .
Quantification of PGE 2 and TxB2
Stomach samples from the experimental mice were collected at the end of the experiment, frozen over dry ice and stored in −80°C till further experiment. The level of PGE 2 was quantified as a marker of COX activity. COX and cytochrome P450 mediated metabolites of arachidonic acid were extracted from tissue samples and quantified as described below [40] .
Tissues (10-60 mg) were spiked with 400 μL + 100 μL methanol and 10 μL of a 400 nM solution containing deuterated oxylipins and subsequently homogenized with a bead beater. Samples were then centrifuged at 16,100 g for 10 min; the supernatant was diluted with 1.5 mL 80:20 v/v water/methanol with 0.1% acetic acid, and then loaded onto Waters Oasis-HLB cartridges. The cartridges were washed twice with 1.5 mL 80:20 v/v water/methanol with 0.1% acetic acid, and dried under low vacuum for 20 min. SPE cartridges were eluted using 0.5 mL methanol and 1.5 mL ethyl acetate into 2 mL Eppendorf vials containing 6 μL 30% glycerol in methanol. Methanol and ethyl acetate were then evaporated from the samples using a Speed-Vac. The residues were reconstituted in 50 μL methanol, vortexed, and filtered prior to LC-MS/MS analysis. Chromatographic separation was performed using a Phenomenex Eclipse C18 column (150 × 4.6 mm; 5 μm). The analysis was carried out using an Agilent 1200 Series LC system coupled to an AB Sciex 4000 Qtrap-mass spectrometer in negative electrospray ionization mode. Samples were injected (5 μL) and separated using a gradient method over 21 min at 0.4 mL/min using acetonitrile/methanol (84:16) and water mobile phases, each containing 0.1% acetic acid. Quantification of oxylipins was calculated from constructed calibrations curves for each analyte, with respect to their deuterated internal standards [40] .
The plasma samples were collected as discussed earlier. The levels of PGE 2 and TxB2 were quantified in the plasma (approximately 250 μL) of animals as per established procedure [40] .
Statistical analysis
Graphpad prism 4.03 (GraphPad Software, San Diego, CA, USA) was used for statistical calculation. Data are presented as the mean ± standard deviation or standard error of the mean of 3-5 readings. One-way ANOVA followed by Tukey's multiple comparison test was used for calculating statistical significance. Differences between data sets were considered as significant when the p value was smaller than 0.05.
Results
Diclofenac causes ulcers in stomachs of mice
Ulceration was observed 6 h post dosing of Swiss Webster and C57BL6 mice with DCF (Fig. 1) . Since 100 mg/kg was the lowest in a series of ascending doses of diclofenac evaluated to give clear ulceration in the time frame investigated, this dose was selected to further investigate the effects of sEH inhibition on gastric erosion. The gastric ulcer score returned to normal levels 18 h after dosing mice with a single DCF (100 mg/kg) dose implying that gastric ulcers are reversible and will heal without intervention if the administration of the NSAID is stopped.
In general, NSAIDs/diclofenac-induced gastric lesion are categorized as 1) gastric mucosa erosion that is defined as acute mucosal inflammatory process and mucosa injury as loss of superficial epithelium above muscular mucosa, and 2) gastric acute ulcer that is defined as deep defect of mucosa, usually it is breach in muscularis mucosa of GI tract and begin as erosions. In our model, since the most of the diclofenac-induced mucosa injury is the deeper than muscular mucosa, we overall considered it as an acute gastric ulcer.
TPPU decreases diclofenac-induced gastric ulcer
Prophylactic treatment with TPPU significantly (p b 0.001) mitigated the ulcerative effects of DCF in Swiss Webster mice (Fig. 1) . Genetic deletion of sEH also significantly (p b 0.001) prevented the formation of DCFinduced gastric ulcers (Fig. 1) . Pre-treatment with omeprazole also decreased NSAID-induced stomach ulcers [7] (Fig. 1). 
TPPU does not affect pH of gastric content
Parietal cells of epithelial gastric glands in the gastric mucosa produce gastric acid, which is secreted into the lumen of the stomach. Gastric acid helps in the digestion of food, but it can aggravate existing stomach ulcers. The pH of the gastric content of mice treated with the vehicle was found to be approximately 4. This is in accordance with the published literature [36, 41] . Treatment with DCF slightly decreased the pH of stomachs, but TPPU treatment normalized this trend. A similar gastric pH of 4 was observed in the sEH knockout mice treated with DCF. In this study, omeprazole administration increased the pH of stomachs as reported by published literature [42] (Fig. 2) .
TPPU does not alter concentration of diclofenac in plasma
The mean plasma concentration of DCF was 4 μg/mL in the mice those received DCF or DCF + TPPU. However, the concentration of DCF in plasma decreased in mice receiving OME, but the decrease was not statistically significant [43] . Diclofenac is known to be metabolized by uridine 5′-diphosphoglucuronosyl transferase 2B7, cytochrome P450s (CYP) 2C9 and 3A4 [44] . Omeprazole is known to increase the activity of CYP3A4 [4] . We measured the concentration of DCF and omeprazole to evaluate if omeprazole treatment increased the metabolism of DCF. Though the mean concentration of diclofenac in plasma of mice treated with only diclofenac was approximately 2 times higher than the mice treated with DCF + OME the difference in concentration in both the groups was not significant which could be due to wide variation in DCF concentration and a low number of animals (n = 4). Similarly, the mean plasma concentration of DCF in sEH knockout mice was not significantly different than other groups. Alterations in blood levels of TPPU and DCF was not observed when they were co-administered. Seven hours after TPPU administration, the concentration in plasma was still higher than its IC 50 of 8 nM on the affinity purified recombinant mouse sEH [29] (Table 1) .
The concentration of omeprazole in plasma was lower than TPPU even though the dose of omeprazole was higher. This may be due to a very short half-life of omeprazole monitored in the blood i.e. 5-15 min. Though the concentration of omeprazole in the blood decreases significantly, the drug still binds to H + K + -ATPase in the stomach where it decreases acid secretion [45, 46] . The acidity of the stomach is maintained by histamine H2 receptors and proton pumps [47] . Helander et al. demonstrated that 16 h after radioactive omeprazole administration, the radioactivity of the stomach was 100 times higher than blood [48] . The concentration of TPPU in plasma was similar to the previously published literature [4] . Like TPPU, omeprazole appears to show excellent target occupancy.
TPPU decreases levels of inflammatory markers in serum of diclofenac treated mice
DCF-induced gastrointestinal ulcers were associated with a significant increase (p b 0.05) in the levels of inflammatory markers TNF-α and IL-6 in serum when compared with mice receiving vehicle only. Treatment with TPPU, OME and sEH gene knockout normalized the level of these cytokines in serum of mice those received DCF (Fig. 3) . Stomachs from mice exposed to DCF exhibited ulcers and hemorrhagic streaks. Pre-treatment with the sEHI TPPU, omeprazole (OME), or (F) sEH knock out (KO) decreased stomach ulceration as shown at 7× under a dissecting microscope. (E) Histopathological observation of tissue section complemented anatomical observation. Morphology of gastric mucosa of vehicle treated Swiss Webster mice looked normal while ulceration was observed on stomachs of DCF treated mice. Luminal surface necrosis tissue debris is shown as highlighted area and it's beneath granulation tissue formation is noticed. Ulceration was minimal in mice treated with DCF + TPPU. Minimal glandular cystic injury/erosion on surface of the mucosal layer in TPPU pre-treated mice is shown with an arrow. Omeprazole also minimized gastric erosion due to DCF. Minimal erosion on surface of mucosal layer is pointed by arrow. (G) Gastric mucosa of C57BL6 mice was normal but ulceration in mucosa (highlighted area) was observed in DCF treated mice. Mucosa with minimal injury/erosion and predominant reactive epithelial changes is seen in stomachs of sEH knockout mice. Doses of TPPU and OME were 0.1 mg/kg and 50 mg/kg respectively. DCF-induced apoptosis of gastric cells. Gene deletion of sEH also protected mice from apoptotic effects of DCF (Fig. 4) .
TPPU decreases diclofenac-induced gastric epithelial cell apoptosis
Diclofenac does not affect activity of the sEH
We did not observe any effect of DCF on the activity of sEH when assayed in vitro or in vivo. Inhibition of sEH by TPPU was not observed in vitro which was likely due to diffusion of the inhibitor from enzyme due to dilution of stomach homogenate during the enzyme assay. No sEH activity was observed in stomach homogenates of sEH KO mice (Fig. 5A ).
TPPU and OME do not affect activity of COX
Diclofenac significantly inhibited COX activity in the stomachs of treated mice which is evident from a significant decrease in the level of PGE 2 in comparison to level of PGE 2 in stomachs of mice treated with vehicle. Treatment with TPPU and/or OME did not increase the activity of COX, and these agents also did not further decrease the activity of COX (Fig. 5B) . The accurate quantification of levels of TxB2, EETs and DHETs in stomach samples was not complete due to insufficient tissue samples (b 50 mg).
Diclofenac and omeprazole alters level of PGE 2 /TxB2
Diclofenac significantly decreased the levels of TxB2/PGE 2 in plasma of mice in comparison to mice treated with vehicle. Levels of TxB2 was below the level of detection (20 pM) in mice treated with only DCF. TPPU and omeprazole increased the level of TxB2/PGE 2 in DCF treated mice (Fig. 5C ).
Discussion
Severe ulceration in the stomach of Swiss Webster mice was observed 6 h after a single administration of DCF. The resolution of this ulceration was time dependent with an apparent return to control levels at 18 h after DCF dose. Stomach ulcers were associated with an increase in the levels of TNF-α and IL-6 in serum and an increase in apoptosis in the epithelial mucosal layer. Pre-treatment of TPPU (0.1 mg/kg/day) for 7 days significantly decreased DCF-induced stomach ulcers and caused a significant decrease in levels of TNF-α and IL-6, as well as the degree of apoptosis. Unlike omeprazole, this anti-ulcer effect of TPPU was not associated with a significant elevation of the gastric pH. The ulcerative potential of DCF was also decreased by a 500-fold higher concentration of OME, a commonly used medicine for the management of NSAID-induced peptic ulcers by elevating gastric pH.
Elevating the pH of the stomach has been associated with alleviation and prevention of NSAID-induced peptic ulcers. Use of alkaline agents, histamine H2 blocker and PPI were found to decrease NSAID-induced ulcers. These pharmacological agents are a part of the management of NSAID-induced gastric ulcers [47] [48] [49] 7] . A decrease in gastric juice volume and an increase in gastric pH and gastric intramucosal pH has been observed with administration of PPIs including OME [50] . However, 
Table 1
Concentration of different drugs in plasma of mice.
Group
Drug concentration in (ng/mL) Diclofenac TPPU Omeprazole Diclofenac 4500 ± 2000 --Diclofenac + TPPU 4900 ± 560 63 ± 5 -Diclofenac + omeprazole 1400 ± 300 -6 ± 2 Diclofenac + sEH KO 880 ± 520 --Diclofenac (DCF) was administered to Swiss Webster and sEH knock out mice orally at a dose of 100 mg/kg and blood samples were collected after 6 h at the time of sacrifice. For prevention of ulcers, the sEH inhibitor TPPU (0.1 mg/kg/day) was administered in drinking water for 7 days and administration was stopped 1 h before of DCF administration. Similarly, last dose of omeprazole (50 mg/kg, p.o., 5 days) was administered before 1 h of DCF administration. Values are presented as mean ± standard error of mean of 4 readings. the ulcer protective agent (sucralfate) and prostaglandin analogs including misoprostol, arbaprostil, enprostil and rioprostil [47] which do not alter pH of gastric acid also are reported to cure gastric ulcers. Sucralfate is shown to reduce ulcers by physically covering and protecting the ulcer area. Though gastric acid does not create ulcers in the stomach of healthy humans, it can aggravate previously formed ulcers. Prostaglandin is known to alleviate the harmful effects of acid by stimulating the release of bicarbonate and mucous which functions as a barrier for the epithelial cells of the stomach [47] . The anti-ulcer effect of the sEH inhibitor TPPU as shown here is not mediated by dramatically elevating the pH of the stomach. The probable mechanism leading to healing of ulcers by TPPU is inhibition of the degradation of fatty acid epoxides by the sEH. Major anti-inflammatory fatty acid epoxides include epoxyeicosatrienoic acids (EETs) derived from arachidonic acid through the action of cytochrome P450s enzymes in the stomach tissue. These EETs also block ER stress and the associated activation of the apoptotic pathways. In a similar study, it was observed that TPPU decreased DCF-induced intestinal ulcers and this anti-ulcer effect was correlated with significant increases in EETs in plasma of animals due to the prevention of its metabolism [6] . Anti-inflammatory properties of EETs have been reported earlier [51, 52, 53] . Anti-inflammatory effects of sEH inhibitors are associated with the decrease in the levels of TNF-α [22, 6] and IL-6 [26, 6] .
In this study, DCF-induced gastric ulcers were associated with an increase in the serum levels of TNF-α. Prophylactic treatment of TPPU, OME and gene deletion of sEH decreased ulceration which correlated with normalization of levels of TNF-α and IL-6. Levels of these cytokines and NSAID-induced gastric ulcers have previously been associated [12] . Specifically, NSAID-induced small intestinal and gastric ulcers were reduced by a TNF-α synthesis inhibitor [54, 55] . Similarly, indomethacininduced inflammatory bowel disease was alleviated by the antibody to TNF-α or gene deletion of TNF-α [56, 8] . TNF-α mediated ulceration involves apoptosis [57] .
An increase in apoptosis, evident from TUNEL staining, was noticed in gastric ulcers in mice treated with DCF. NSAID-induced gastric apoptosis could be due to an increase in the levels of TNF-α and its action via TNF receptor 1 (TNFR1) [16, 58, 59] . A baseline level of 2-3% of apoptotic cells in the epithelial layer of the stomach is normal and the presence of more apoptotic cells than this is considered an indication of mucosal injury by stimuli such as NSAIDs [16] . Toxicity-induced cleavage of the DNA into fragments and production of DNA strand breaks are detected by nick end labeling [60] . A decrease in apoptosis of gastric epithelial cells was observed in the mice pre-treated with TPPU and OME followed by DCF. Omeprazole was reported to decrease NSAID (indomethacin)-induced gastropathy and cold stress-induced apoptosis of gastric epithelial cells [61] . A similar effect was also noticed with gene deletion of sEH.
We observed a wide difference in the concentration of DCF in plasma of mice. This could be due to inter-animal variation in metabolizing DCF and uneven blood loss at the site of ulceration. Pretreatment of OME and TPPU reduced variation in the concentration of DCF. Earlier, we reported that a significant loss of hemoglobin in animals treated with DCF using intestinal ulcer model [6] . However, these data are important because they indicate the range of concentration of diclofenac that is ulcerogenic in mice. The concentration of TPPU in plasma is important because it will help researchers to design further experiments accordingly. In this study, we administered TPPU chronically, but evaluation of the anti-ulcer effect of TPPU after a single dose, much like omeprazole is of interest. It is expected that plasma concentration of 60 ng/mL of TPPU is required to observe possible anti-ulcer effects.
Ulcerative effect of DCF was associated with a significant decrease ( ⁎ p b 0.05, vs vehicle) in the levels of TxB2/PGE 2 in the plasma of animals. Pretreatment of the sEH inhibitor and OME minimized the decrease in the levels of TxB2/PGE 2 in DCF treated mice (Fig. 5c) . Levels of PGE 2 in the plasma of animals treated with vehicle, DCF, DCF + TPPU and DCF + OME were not statistically (data not shown) different whereas the levels of PGE 2 in gastric samples were significantly decreased in the animals treated with DCF, DCF + TPPU and DCF + OME (Fig. 5B ) in comparison to vehicle. Quantifying the levels of TxB2/PGE 2 in stomach samples could have been better, but we were limited by the amount of stomach samples. In the DCF + OME group, the decrease of TxB2/PGE 2 was least in comparison to other DCF treated groups. This could be due to the decrease in the levels of DCF in plasma of animals administered with OME. There is also an immunoassay-based method to quantify the activity of COX in vitro which uses supplemental arachidonic acid and measures the level of TxB2 and PGE 2 produced [62] [63] [64] . The activity of COX in this assay may vary depending on the amount of arachidonic acid used unlike the assay performed by us which uses arachidonic acid available to the COX in the cells of the stomach.
Conclusion
Small molecule sEH inhibitors are in clinical trials to treat inflammation and are in development for managing pain [65, 66] . Since sEH inhibitors are likely to be used clinically with the standard of care, it is likely that they will be used with NSAIDs to control inflammation synergistically. Gastrointestinal erosion often is associated with NSAID use, an added benefit of co-administration with sEH inhibitors is reduction in ulceration. This anti-ulcer effect was supported by results from sEH knockout mice in diclofenac-induced gastric ulcer model. Therefore, co-administration of sEH inhibitors with NSAIDs can decrease dose and ulcerative potential of NSAIDs. Clinical studies are required to test these hypotheses in man and companion animals.
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